Key result
Once-weekly anticoagulants such as idraparinux offer the potential to improve adherence and clinical outcomes compared to daily warfarin for the treatment and prevention of thromboembolism.
Why the study?
Does a once-weekly anticoagulant improve adherence compared to daily dosing in patients requiring long-term treatment and secondary prevention of thromboembolism?
Population
Patients requiring long-term treatment and secondary prevention of thromboembolism
Comparison
Once-weekly anticoagulants (e.g., idraparinux) vs Daily oral anticoagulation (e.g., warfarin)
Design
Review
Authors
Loading...
May enhance adherence in long-term use; leaves open confirmation of outcome benefits versus daily regimens.
Does a once-weekly anticoagulant improve adherence compared to daily dosing in patients requiring long-term treatment and secondary prevention of thromboembolism?
Once-weekly anticoagulants like idraparinux may improve patient adherence and clinical outcomes compared to daily warfarin therapy.
Maillardet et al. (2009) conducted a review in Thromboembolism. Once-weekly anticoagulants (e.g., idraparinux) vs. Warfarin once daily was evaluated. Once-weekly anticoagulants such as idraparinux offer the potential to improve adherence and clinical outcomes compared to daily warfarin for the treatment and prevention of thromboembolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: